This is the point I have made over some time: there is no evidence whatsoever that BIT225 has any effect in treatment non-responders, and no particular reason to suspect that it would. To prove it either way will require a new series of trials, sufficiently expensive to absolutely require support from a larger company, and given that current or nearly available treatments give 97-98% cure, is a market of 2-3% of first world HCV actually large enough to be commercially viable. Back in 2012 I asked this company about what their reaction was to sofosbuvir, and got the response "the market is big enough for other drugs", followed by 4 years of further trials with PEG-riba when that combination was clearly dead in the water. This company has been way too slow on its feet.
- Forums
- ASX - By Stock
- BIT
- Thoughts
Thoughts, page-17
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
|
|||||
Last
1.7¢ |
Change
-0.011(39.3%) |
Mkt cap ! $15.33M |
Open | High | Low | Value | Volume |
2.2¢ | 2.5¢ | 1.7¢ | $374.7K | 18.97M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
19 | 1266038 | 1.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.8¢ | 689330 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 1114863 | 0.017 |
13 | 1640362 | 0.016 |
11 | 1033562 | 0.015 |
1 | 250000 | 0.014 |
4 | 1280000 | 0.013 |
Price($) | Vol. | No. |
---|---|---|
0.018 | 689330 | 2 |
0.019 | 354299 | 4 |
0.020 | 1628000 | 6 |
0.021 | 110000 | 2 |
0.022 | 388947 | 2 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |